A systematic review of meta-analyses of the efficacy of oral atypical antipsychotics for the treatment of adult patients with schizophrenia.
about
Iloperidone in the treatment of schizophrenia: an evidence-based review of its place in therapyLow dose morphine adjuvant therapy for enhanced efficacy of antipsychotic drug action: potential involvement of endogenous morphine in the pathophysiology of schizophrenia.CYP1A2 polymorphism -1545C > T (rs2470890) is associated with increased side effects to clozapine.Quetiapine versus aripiprazole in the management of schizophrenia.Efficacy, tolerability, and safety of aripiprazole once-monthly versus other long-acting injectable antipsychotic therapies in the maintenance treatment of schizophrenia: a mixed treatment comparison of double-blind randomized clinical trialsMetabolic Disturbances, Side Effect Profile and Effectiveness of Clozapine in Adolescents.Drug treatment developments in schizophrenia and bipolar mania: latest evidence and clinical usefulness.Pharmacogenomics can improve antipsychotic treatment in schizophrenia.New second-generation long-acting injectable antipsychotics for the treatment of schizophrenia.Evaluation of the pharmacokinetics, safety and clinical efficacy of ziprasidone for the treatment of schizophrenia and bipolar disorder.Systematic Literature Review of the Methods Used to Compare Newer Second-Generation Agents for the Management of Schizophrenia: A focus on Health Technology Assessment.Prediction of Efficacy of Vabicaserin, a 5-HT2C Agonist, for the Treatment of Schizophrenia Using a Quantitative Systems Pharmacology Model.Clozapine in Reducing Aggression and Violence in Forensic Populations.Canadian Guidelines for the Pharmacological Treatment of Schizophrenia Spectrum and Other Psychotic Disorders in Children and Youth.Influence of FMO1 and 3 polymorphisms on serum olanzapine and its N-oxide metabolite in psychiatric patients.
P2860
Q28078158-21FEA941-568B-498B-A5DF-D592BEA0E053Q30455274-7D591516-2AFD-4B3F-A690-672466C61824Q35098697-385E1E64-DA9D-4E0E-8448-6B725C54A7B3Q35852537-BD0EEC71-CC99-4A2F-AB14-93DB84050E97Q36001512-650DF9B9-7CAC-4F5B-9FE9-6C0CE0EB325EQ36997233-0D19A581-10D9-460A-8B4D-BAD89BC76E46Q38076126-0A1654BB-2E99-4688-9217-8B4B75AA2556Q38100731-DB4CE735-7931-4E73-8509-4349858C68E6Q38125213-E7FD52A5-3D4B-4840-9EFB-F2CBD4DF78E3Q38284625-6B970B1C-4DC1-4EDD-BC9E-B9F556ABDA3CQ38473914-E3D64D0F-25CF-4C25-83FC-3E69C54AE8ABQ39267434-13111ECB-1E9B-46F0-AC28-33B555179BF9Q39393088-57C1A223-AAFA-48D2-AEDF-594B54241815Q47307661-0FFEF05E-CBBA-45FE-B870-2BFE4BE04BE5Q50736144-EBB2DD27-D298-4FA9-B66E-1614F8720605
P2860
A systematic review of meta-analyses of the efficacy of oral atypical antipsychotics for the treatment of adult patients with schizophrenia.
description
2011 nî lūn-bûn
@nan
2011 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
A systematic review of meta-an ...... t patients with schizophrenia.
@ast
A systematic review of meta-an ...... t patients with schizophrenia.
@en
A systematic review of meta-an ...... t patients with schizophrenia.
@nl
type
label
A systematic review of meta-an ...... t patients with schizophrenia.
@ast
A systematic review of meta-an ...... t patients with schizophrenia.
@en
A systematic review of meta-an ...... t patients with schizophrenia.
@nl
prefLabel
A systematic review of meta-an ...... t patients with schizophrenia.
@ast
A systematic review of meta-an ...... t patients with schizophrenia.
@en
A systematic review of meta-an ...... t patients with schizophrenia.
@nl
P2860
P921
P1476
A systematic review of meta-an ...... t patients with schizophrenia.
@en
P2860
P304
P356
10.1517/14656566.2011.626769
P407
P577
2011-10-17T00:00:00Z